Total: $386.5M

Company
(Symbol)#
(M)

Type Of
Financing

Number Of
Shares,
Units
Or
Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details
(Date)@


Akesis
Pharmaceuticals
Inc.
(OTC BB:AKES)

Private placement of stock and warrants

2S and 1W

$4

The shares are being sold at $2 each; the three- year warrants are exercisable at $3 per share (1/6)

Amarin Corp.
plc
(UK; AMRN)

Private placement of stock and warrants

0.8S and 0.28W

$2

The shares were sold at $2.50 each to existing investor Tony Ryan; the warrants are exercisable at $3.06 per share (1/23)

Biomira Inc.
(Canada; BIOM)

Private placement of stock and warrants

10.572S and 2.643W

$16.1

Units consisting of one share and 25% of a warrant were sold at $1.52 apiece; each whole warrant is exercisable for 42 months at $1.52 per share; Rodman & Renshaw LLC was placement agent (1/27)

Biopure Corp.
(BPUR)

Sale of stock and warrants

4.11S and 4.11W

$3.37

The shares were sold at $3.37 each; the warrants are exercisable at $1.025 each; Dawson James Securities Inc. and Noble International Investments Inc. were underwriters (1/17)

Corgenix
Medical Corp.
(OTC BB:CONX)

Private placement of convertible stock, notes and warrants

N/A and 18.8W

$3.36

In one deal Barron Partners LP bought $2M in pre- ferred stock, convertible into about 5.7M common shares; it also got 15M warrants exercisable from $0.40 to $0.60 per share; in a second deal investors bought $1.36M in convertible notes; they got 3.8M warrants exercisable at $0.23 per share; Ascendiant Securities LLC was placement agent for the deals (1/3)

Cytokinetics
Inc.
(CYTK)

Registered direct offering

5.5S

$33

Federated Kaufmann and Red Abbey Venture Partners purchased the shares at $6.60 each; Pacific Growth Equities LLC was adviser in the deal (1/18)

DOR
BioPharma
Inc.
(AMEX:DOR)

Stock purchase agreement

N/A

$6

Fusion Capital Fund II LLC agreed to purchase up to $400,000 of DOR stock at the market price each month for 15 months; DOR will control the timing and amount of stock sold (1/19)

GammaCan
International
Inc.
(Israel;
OTC BB:GCAN)

Private placement of securities

1.6S and
1.5W

$1.2

The stock and warrants were placed privately in two separate deals (1/17)

Genmab A/S
(Denmark; CSE:
GEN)

Private placement of stock

5.75S

DKK845.2 ($136)

The shares were sold to institutional investors; underwriters were Merrill Lynch & Co., ABN AMRO Rothschild, and Alfred Berg SE (1/27)

GW
Pharmaceuticals
plc
(UK; AIM:GWP)

Private placement of stock and warrants

6.166S and 1.85W

£8.6 ($15)

The shares were placed with a U.S.-based institutional investor at 139.6 pence each; half of the five-year warrants are exercisable at £1.61 per share and half at £1.745 per share; Seven Hills Partners LLC was placement agent (1/4)

Intercytex
Group plc
(UK; AIM:ICX)

Private placement of stock

13.89S

£15 ($26.4)

The company gained a listing on the AIM through the deal, in which existing investors purchased £4.2M of stock, and new investors bought £10.8M worth, all at 108 pence per share; Piper Jaffray Ltd. was the deal's nominated adviser and broker (1/27)

Lipoxen plc
(UK; AIM:LPX)

Private placement of stock

28S

£3.8 ($6.7)

Shares were priced at 13.5 pence each in the deal; Canaccord Adams Ltd. was broker and Grant Thornton Corporate Finance was nominated adviser (1/17)

Matritech Inc.
(AMEX:MZT)

Private placement of convertible notes and warrants

N/A and 7.5W

$7

The 15% notes are due in January 2009 and are convertible in 10.77M shares; five-year warrants in the deal are convertible into 6.46M shares at $0.67 per share, and the placement agents got warrants to buy 1.04M shares at $0.65 per share; investors included SDS Capital Partners and H&Q Life Science Investors (1/17)

Medicure Inc.
(Canada; TSE:
MPH)

Bought-deal financing

7.75S

C$12 ($10.3)

Underwriters led by Blackmont Capital Inc. and including National Bank Financial Inc. purchased the shares at C$1.55 each; totals include 1.25M shares bought via their overallotment option (1/4)

NanoLogix
Inc.
(PK:NNLX)

Investment

ND

$0.75

The Nutmeg Group provided a financing commitment of $0.75M; terms were not disclosed (1/12)

NexMed Inc.
(NEXM)

Private placement of stock and warrants

9.347S and 3.739W

$8.32

The shares were sold at $0.89 each; the four-year warrants are exercisable at $1.11 per share; investors included Southpoint Capital Advisors LP and Loeb Partners Corp. (1/25)

NitroMed Inc.
(NTMD)

Registered direct offering

6.1S

$62.5

The shares were sold from a shelf registration at $10.25 each; JP Morgan Securities Inc. and Thomas Weisel Partners LLC were placement agents (1/25)

Pharming
Group NV
(the Netherlands;
Euronext:PHARM)

Private placement of stock and warrants

4.5S and 0.675W

€17.1 ($20.5)

The shares were sold at €3.80 each, and the two- year warrants are exercisable at €4 per share; Amsterdams Effectenkantoor, Fortis Bank and Rabo Securities were placement agents (1/25)

Procyon
Biopharma
Inc.
(Canada;
TSE:PBP)

Private placement of special warrants and units

78.6SW

C$18.1 ($15.7)

The special warrants, priced at C$0.23 each, entitle the holder to one common share and a five- year warrant to purchase one share at C$0.35; lead agent Dundee Securities Corp. was joined by Loewen, Ondaatje, McCutcheon Ltd. and Desjardins Securities Inc. in the deal (1/19)

Provectus
Pharmaceuticals
Inc.
(OTC BB:PVCT)

Private placement of equity

ND

$8.3

Network 1 Financial Securities Inc. and Chicago Investment Group were placement agents for the deal, terms of which were not disclosed (1/5)


Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange.

No Comments